Kynmaro denied by CHMP, still time to get in to AEGR
The denial of the MAA by the CHMP bodes well for AEGR because AEGR won't have to split market share with ISIS. The CHMP denial of ISIS appears to be related to the cancer concerns that were also raised by the US FDA.
This means AEGR should be able to capture 100% of the total available market (TAM) and that means twice as much money for the company and shareholders. The stock price of AEGR should rise strongly on this news!
With about 6,000 people needing treatment for homozygous familial hypercholesterolemia at $300K per patient per year, the market is about $1.8 billion. Now that AEGR won't have to split any of the profits with ISIS they will capture the majority of the market share.